Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 125,989 | 220,797 | 132,262 | 95,823 | 120,122 |
| Marketable Securities | 124,659 | 21,106 | 32,606 | 41,966 | 28,114 |
| Receivables | 22,802 | 17,415 | 14,158 | 15,443 | 12,847 |
| Inventories | 7,594 | 7,442 | 7,243 | 5,673 | 5,002 |
| TOTAL | $295,097 | $278,968 | $196,760 | $169,186 | $182,123 |
| Non-Current Assets | |||||
| PPE Net | 608 | 580 | 566 | 689 | 823 |
| Investments And Advances | 4,641 | 203 | 481 | 4,502 | 6,507 |
| Other Non-Current Assets | 1,597 | 2,098 | 2,767 | 3,934 | 4,180 |
| TOTAL | $6,846 | $2,881 | $3,814 | $9,125 | $11,510 |
| Total Assets | $301,943 | $281,849 | $200,574 | $178,311 | $193,633 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 19,685 | 23,754 | 18,158 | 16,538 | 14,083 |
| Accrued Expenses | 9,029 | 6,849 | 4,985 | 10,814 | 8,152 |
| Other current liabilities | 4,073 | 3,620 | 3,197 | 3,860 | 3,553 |
| TOTAL | $32,787 | $34,223 | $26,340 | $31,212 | $25,788 |
| Non-Current Liabilities | |||||
| Long Term Debt | 121,709 | 97,813 | 97,590 | 98,551 | 98,518 |
| Other Non-Current Liabilities | 121,932 | 119,499 | 116,778 | 113,760 | 111,320 |
| TOTAL | $243,641 | $217,312 | $214,368 | $212,311 | $209,838 |
| Total Liabilities | $276,428 | $251,535 | $240,708 | $243,523 | $235,626 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 42,199 | 42,114 | 36,130 | 34,122 | 30,866 |
| Common Shares | 115 | 112 | 99 | 89 | 84 |
| Retained earnings | -768,710 | -745,037 | -711,634 | -679,348 | -653,332 |
| Other shareholders' equity | 236 | -31 | -37 | 12 | -134 |
| TOTAL | $25,515 | $30,314 | $-40,134 | $-65,212 | $-41,993 |
| Total Liabilities And Equity | $301,943 | $281,849 | $200,574 | $178,311 | $193,633 |